Anlon Healthcare (NSE:AHCL) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AHCL Anlon Healthcare Ltd NSE:AHCL
21 GF Score
Price ₹20.04
! 6 Warning Signs
View Full Analysis

What is Anlon Healthcare Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Anlon Healthcare's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Anlon Healthcare's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was ₹0 Mil. Anlon Healthcare's annualized EBITDA for the quarter that ended in Jun. 2026 was ₹626 Mil. Anlon Healthcare's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Anlon Healthcare's Debt-to-EBITDA or its related term are showing as below:

NSE:AHCL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.03   Med: 5.17   Max: 10.68
Current: 0.03

During the past 5 years, the highest Debt-to-EBITDA Ratio of Anlon Healthcare was 10.68. The lowest was 0.03. And the median was 5.17.

NSE:AHCL's Debt-to-EBITDA is ranked better than
95.28% of 678 companies
in the Drug Manufacturers industry
Industry Median: 1.64 vs NSE:AHCL: 0.03

Anlon Healthcare  (NSE:AHCL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Anlon Healthcare Debt-to-EBITDA Related Terms

Anlon Healthcare Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Anlon Healthcare's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anlon Healthcare Debt-to-EBITDA Chart

Anlon Healthcare Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Debt-to-EBITDA
10.49 5.50 5.19 2.06 0.91

Anlon Healthcare Quarterly Data
Jun24 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial N/A N/A N/A 0.91 N/A

NSE:AHCL vs ZTS: Debt-to-EBITDA Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anlon Healthcare Debt-to-EBITDA vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Anlon Healthcare's Debt-to-EBITDA falls into.


NSE:AHCL
21GF Score
Anlon Healthcare Ltd NSE:AHCL
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anlon Healthcare Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Anlon Healthcare's Debt-to-EBITDA for the fiscal year that ended in Mar. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(375.59 + 60.937) / 477.72
=0.91

Anlon Healthcare's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=( + 0) / 626.02
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Anlon Healthcare Business Description

Other Exchanges 544497:India
Address Kalawad Road, 101/102, Silvercoin Complex, Opposite Crystal Mall, Rajkot, GJ, IND, 360 005
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
21GF Score

Get the complete analysis for NSE:AHCL

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹20.04
Price